Arjun Goyal, MD, MPhil, MBA

Arjun Goyal, MD, is Co-Founder and Managing Director of Vida Ventures, a leading U.S.-based life sciences venture capital firm with approximately $1.7 billion under management. Dr. Goyal focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. In addition to Affini-T, Dr. Goyal serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Alterome Therapeutics and Centessa Pharmaceuticals (NASDAQ: CNTA) and has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics, acquired by Gilead, Peloton Therapeutics, acquired by Merck & Co., and Asklepios Bio, acquired by Bayer. Before co-founding Vida Ventures in 2017, Dr. Goyal was a life sciences investor at 5AM Ventures. Dr. Goyal has received multiple awards for his work, including the Advance Award for Technology and Entrepreneurship from the Australian Government. Dr. Goyal currently serves on the Committee for the American Australian Association Education Fellowship.

Dr. Goyal received his BSc in medical science, his MBBS degree from the Universities of Melbourne and the University of Oxford and completed postgraduate clinical training in internal medicine in Sydney. He received his MPhil. in bioscience enterprise from the University of Cambridge and his MBA from Harvard Business School.